Faculty profile

Darryl Falzarano

ResearcherVaccine and Infectious Disease OrganizationUniversity of Saskatchewan

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Saskatchewan directory, so their courses may be missing. Find their university profile.

Darryl Falzarano

Researcher

Vaccine and Infectious Disease Organization

Health Sciences

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
37 publications in the last five years, latest in 2026.
Senior (last) author on 3 recent papers, a sign of leading a research group.
Principal investigator on 9 research grants (8 CIHR, 1 NSERC), most recently in 2024.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Vaccine Animal Model Sars-Cov-2 Immune Enhancement One Health Covid-19 Emerging Virus Immune Response

Latest papers

FGFR signaling and neddylation facilitate SARS-CoV-2 infection by modulating interferon induction and viral entry, respectively.
iScience · 2026
Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.
Vaccines · 2026
Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.
Vaccine · 2025

All 63 publications

Latest funding

Mechanisms driving convergent evolution of SARS CoV-2 during a pandemic
CIHR · 2025 · Co-investigator
$1,143,675
5th Symposium of the Canadian Society for Virology
CIHR · 2024 · Nominated PI
$20,000
Reverse genetic analysis of mechanisms underlying convergent evolution of SARS-CoV-2 variants of concern and accessory protein functions
CIHR · 2023 · Co-investigator
$100,000

All 17 grants and awards

63 publications.

FGFR signaling and neddylation facilitate SARS-CoV-2 infection by modulating interferon induction and viral entry, respectively.

Felix-Lopez A, Lopez-Orozco J, Elaish M, Fayad N, Xu Z, Woldemariam T, Hassan BB, Panigrahi R, Khan JQ, Rohamare M, Mayers I, Glover JNM, Wilson JA, Falzarano D, Kumar A, Hobman TC

iScience2026

DOI: 10.1016/j.isci.2025.114566 PMID: 41585476

Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.

Blanchette LJ, Bolduc M, Woldemariam T, Yousefi M, Rabezanahary H, Olivera-Ugarte SM, Garneau C, Angers M, Shi R, Flamand L, Baz M, Vidal S, Falzarano D, Lemay JF, Leclerc D

Vaccines2026

DOI: 10.3390/vaccines14040349 PMID: 42042825

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Hamonic G, Pastural E, Arora S, Lew J, Cai Y, Scruten E, Buchanan R, ElSherif M, Ye L, Courant T, Ventura RA, Collin N, Daugan M, Gagnon L, Hodgson P, van Drunen Little-van den Hurk S, Falzarano D, Sanche S, Halperin SA, Langley JM, Gerdts V, Racine T

Vaccine2025

DOI: 10.1016/j.vaccine.2025.127748 PMID: 40957309

A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

Pierre Bikorimana J, Caveney NA, El-Hachem N, Mandl GA, Capobianco JA, Stanga D, Abusarah J, Hancock MA, Farah R, Gonçalves MP, Falzarano D, Liao M, Hamonic G, Liu Q, Beaudoin S, Talbot S, Rafei M

iScience2025

DOI: 10.1016/j.isci.2025.113314 PMID: 41054531

Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening.

Rohamare M, Kaushik N, Khan JQ, Balouchi M, Lopez-Orozco J, Kozak R, Hobman TC, Falzarano D, Kumar A, Wilson JA

Viruses2025

DOI: 10.3390/v18010044 PMID: 41600809

MERS-CoV and SARS-CoV-2 infection in diverse human lung organoid-derived cultures.

Chiok KL, Jenik K, Fenton M, Falzarano D, Dhar N, Banerjee A

Journal of virology2025

DOI: 10.1128/jvi.01098-25 PMID: 40965144

Immunogenicity of virus-like particle vaccine candidates against SARS-CoV-2 infection.

Nguyen HT, Garg R, Kroeker A, Gerdts V, Falzarano D, Liu Q

Access microbiology2025

DOI: 10.1099/acmi.0.000925.v3 PMID: 39967742

Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV.

Zadeh VR, Lew JM, Zahoor MA, Santer D, Feld JJ, Falzarano D

Virus research2025Senior author

DOI: 10.1016/j.virusres.2025.199560 PMID: 40113092

Expanding the bat toolbox: Carollia perspicillata bat cell lines and reagents enable the characterization of viral susceptibility and innate immune responses.

Gonzalez V, Word C, Guerra-Pilaquinga N, Mazinani M, Fawcett S, Portfors C, Falzarano D, Kell AM, Jangra RK, Banerjee A, Seifert SN, Letko M

PLoS biology2025

DOI: 10.1371/journal.pbio.3003098 PMID: 40233033

Recruitment of pulmonary intravascular macrophages in SARS-CoV-2 infected hamsters.

Rodrigues CR, Aulakh GK, Kroeker A, Kulkarni SS, Lew J, Falzarano D, Singh B

Cell and tissue research2025

DOI: 10.1007/s00441-025-03958-2 PMID: 40014090

Something wrong or missing on this profile? Suggest a correction

Darryl Falzarano

Research

Latest papers

Latest funding

FGFR signaling and neddylation facilitate SARS-CoV-2 infection by modulating interferon induction and viral entry, respectively.

Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants.

Safety and immunogenicity of COVAC-2, a Sepivac SWE&#x2122; adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity.

Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening.

MERS-CoV and SARS-CoV-2 infection in diverse human lung organoid-derived cultures.

Immunogenicity of virus-like particle vaccine candidates against SARS-CoV-2 infection.

Combination therapy enhances the antiviral activity of IFN-&#x3bb; against SARS-CoV-2 and MERS-CoV.

Expanding the bat toolbox: Carollia perspicillata bat cell lines and reagents enable the characterization of viral susceptibility and innate immune responses.

Recruitment of pulmonary intravascular macrophages in SARS-CoV-2 infected hamsters.

Frequent collaborators

Volker Gerdts

Arinjay Banerjee

Robert Kozak

Steven Machtaler

Steven Theriault

Christopher Richardson

Anand Kumar

Darwyn Kobasa

Mia Biondi

Derek Stein

Craig McCormick

Samira Mubareka

Baljit Singh

Moutih Rafei

Moutih Rafei

Neeraj Dhar

Sébastien Talbot

Tony Mazzulli

Deanna Santer

Yan Zhou

Finlay Maguire

Sriram Subramaniam

Gary Wong

David Safronetz

Kenneth Rockwood

Joyce Wilson

Silvia Vidal

Sultan Darvesh

Alain Lamarre

Jerry Pelletier

Jean-Philippe Julien

Laurent Chatel-Chaix

Karen Mossman

Sharon Walmsley

Andrew Doxey

Anne-Claude Gingras

Louis Flamand

Paul Hodgson

Safety and immunogenicity of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Combination therapy enhances the antiviral activity of IFN-λ against SARS-CoV-2 and MERS-CoV.